Key Highlights
- Third-quarter 2026 total revenues were USD 19.3 million, against USD 8.6 million.
- Net loss was USD 8.1 million, or USD 0.08 per share.
- Management reiterated 2026 Revenue guidance of USD 72 million to USD 76 million.
- Cash, cash equivalents and short-term investments were USD 72.7 million at quarter end.
Codexis (NASDAQ:CDXS) reported third-quarter 2026 total revenues of USD 19.3 million, against an estimate of USD 18.72 million and USD 8.6 million in the same quarter of 2025. The net loss was USD 0.08 per share, against an estimate of a loss of USD 0.10. The company develops enzymes and Manufacturing platforms, including its ECO Synthesis platform for RNAi medicines.
Quarterly Results
Product revenue was USD 15.7 million, against USD 6.8 million, and Research and Development revenue was USD 3.5 million, against USD 1.8 million. For the nine months, total revenues were USD 49.4 million, against USD 31.5 million.
Cost of product revenue was USD 4.0 million, against USD 2.5 million. Research and development expenses were USD 12.6 million, against USD 13.9 million, and selling, general and administrative expenses were USD 10.1 million, against USD 11.2 million. Total costs and operating expenses were USD 26.7 million, against USD 27.6 million, and the loss from operations was USD 7.4 million, against USD 18.9 million.
Interest income was USD 658 thousand, and interest and other expense, net, was USD 1,341 thousand. Net loss was USD 8.1 million, against USD 19.6 million, and net loss per share was USD 0.08, against USD 0.22. For the nine months, net loss was USD 28.8 million, or USD 0.30 per share, against USD 53.6 million, or USD 0.62 per share.
Guidance and Strategy
On the call, management reiterated its 2026 revenue guidance of USD 72 million to USD 76 million. Management said 2026 has been a year of recognition for developers of RNAi medicines and that exploration of enzymatic approaches to manufacturing is building significantly, adding that the ECO Synthesis platform is in the lead in defining alternatives. It said industry dialogue has shifted from proof of concept toward commercial manufacturing.
Financing and Cash
On July 23, 2026, the company entered into an Underwriting agreement for a public offering of 16,666,667 shares of common stock at USD 1.50 per share, which closed on July 27, 2026. The underwriters purchased 1,333,333 additional shares on July 29, 2026. In total, the company issued 18,000,000 shares and received net proceeds of USD 24.9 million after underwriting discounts of USD 1.6 million and offering expenses of USD 0.5 million. USD 26.4 million remained available for sale under its Cantor sales agreement as of September 30, 2026.
After quarter end, the company entered into a USD 60 million senior secured term Loan agreement, of which USD 42.5 million was drawn at closing and used to pay off existing Debt of USD 42 million. Management said the loan provides for 48 months of interest-only payments followed by a 12-month amortization period. The filing states the Interest Rate on the Trinity loans ranges from 10.50% to 11.75% per annum.
Cash, cash equivalents and short-term investments were USD 72.7 million at the end of the third quarter, against USD 78.2 million at the end of 2025. Management said it believes current cash is sufficient to fund planned operations and capital expenditures through 2028.
Weighted average shares used in computing net loss per share were 107,259 thousand, against 90,251 thousand.






Please wait processing your request...